Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

Some patients with low-grade Ta nonmuscle-invasive bladder cancer (LG Ta NMIBC) can experience recurrence after many years.

Among management options for node-positive upper tract urothelial cancer (UTUC), induction chemotherapy added to radical nephroureterectomy (RNU) provides the best cancer control and survival outcomes ...

The Phase I trial will evaluate the safety and efficacy of the company’s drug which targets tumours whilst leaving normal ...

Innate Pharma (IPHA) announced the first patient was dosed in its Phase 1 study, investigating the safety and tolerability of IPH4502, an ...

Chemoablation with mitomycin gel (Jelmyto) for low-grade upper tract urothelial cancer led to a 3-year recurrence-free ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with ...

PRINCETON, N.J. - Recent findings from a study on UroGen Pharma Ltd.'s (NASDAQ: URGN) JELMYTO (mitomycin) for pyelocalyceal solution suggest its effectiveness in long-term disease control for patients ...